ArticleMolecular cell2016
Mediator: A Drawbridge across the Enhancer-Promoter Divide.
Article in Molecular cell, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Transcriptional pause release at enhancers mediates cell identity.NAR cancer · 2025Review
- Single-molecule analysis of transcription activation: dynamics of SAGA coactivator recruitment.Nature structural & molecular biology · 2025Article
- Enhancer selectivity in space and time: from enhancer-promoter interactions to promoter activation.Nature reviews. Molecular cell biology · 2024Review
- Regulation of the RNA polymerase II pre-initiation complex by its associated coactivators.Nature reviews. Genetics · 2023Review
- Temporal analyses reveal a pivotal role for sense and antisense enhancer RNAs in coordinate immunoglobulin lambda locus activation.Nucleic acids research · 2023Article
- RNA polymerase II dynamics shape enhancer-promoter interactions.Nature genetics · 2023Article
- Competing constraints shape the nonequilibrium limits of cellular decision-making.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- Nuclear export restricts Gdown1 to a mitotic function.Nucleic acids research · 2022Article
- Mechanisms of enhancer action: the known and the unknown.Genome biology · 2021Review
- Mediator subunit MED1 is required for E2A-PBX1-mediated oncogenic transcription and leukemic cell growth.Proceedings of the National Academy of Sciences of the United States of America · 2021Article
- Unique Immune Cell Coactivators Specify Locus Control Region Function and Cell Stage.Molecular cell · 2020Article
- Regulation of hepatocyte cell cycle re-entry by RNA polymerase II-associated Gdown1.Cell cycle (Georgetown, Tex.) · 2020Review
- Gene Transcription as a Limiting Factor in Protein Production and Cell Growth.G3 (Bethesda, Md.) · 2020Article
- 50+ years of eukaryotic transcription: an expanding universe of factors and mechanisms.Nature structural & molecular biology · 2019Review
- Multivalent Role of Human TFIID in Recruiting Elongation Components at the Promoter-Proximal Region for Transcriptional Control.Cell reports · 2019Article
- Architecture of Pol II(G) and molecular mechanism of transcription regulation by Gdown1.Nature structural & molecular biology · 2018Article
- Candida glabrata Med3 Plays a Role in Altering Cell Size and Budding Index To Coordinate Cell Growth.Applied and environmental microbiology · 2018Article
- SRC-3 Coactivator Governs Dynamic Estrogen-Induced Chromatin Looping Interactions during Transcription.Molecular cell · 2018Article
- Enhancers and chromatin structures: regulatory hubs in gene expression and diseases.Bioscience reports · 2017Review
Corrections and comments
- Comment on
- Comment on
Authors and funding
2 authors.
Funding
Abstract
Two papers in this issue of Molecular Cell provide insights into how the multisubunit Mediator coactivator complex dynamically links enhancer-bound activators to the RNA polymerase II machinery at the core promoter.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.